Literature DB >> 21632247

Identification of new inhibitors of protein kinase R guided by statistical modeling.

Ruslana Bryk1, Kangyun Wu, Brian C Raimundo, Paul E Boardman, Ping Chao, Graeme L Conn, Eric Anderson, James L Cole, Nigel P Duffy, Carl Nathan, John H Griffin.   

Abstract

We report the identification of new, structurally diverse inhibitors of interferon-induced, double-stranded RNA-activated protein kinase (PKR) using a combined experimental and computational approach. A training set with which to build a predictive statistical model was generated by screening a set of 80 known Ser/Thr kinase inhibitors against recombinant human PKR, resulting in the identification of 28 compounds from 18 chemical classes with <0.1 μM ≤ IC(50) ≤ 20 μM. The model built with this data was used to screen a database of 5 million commercially available compounds in silico to identify candidate inhibitors. Testing of 128 structurally diverse candidates resulted in the confirmation of 20 new inhibitors from 11 chemical classes with 2 μM ≤ IC(50) ≤ 20 μM. Testing of 34 analogs in the newly identified pyrimidin-2-amine active series provided initial SAR. One newly identified inhibitor, N-[2-(1H-indol-3-yl)ethyl]-4-(2-methyl-1H-indol-3-yl)pyrimidin-2-amine (compound 51), inhibited intracellular PKR activation in a dose-dependent manner in primary mouse macrophages without evident toxicity at effective concentrations.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632247     DOI: 10.1016/j.bmcl.2011.04.149

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

Review 1.  Host-directed therapeutics for tuberculosis: can we harness the host?

Authors:  Thomas R Hawn; Alastair I Matheson; Stephen N Maley; Omar Vandal
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

2.  Design and synthesis of novel protein kinase R (PKR) inhibitors.

Authors:  Sagiv Weintraub; Tali Yarnitzky; Shirin Kahremany; Iliana Barrera; Olga Viskind; Kobi Rosenblum; Masha Y Niv; Arie Gruzman
Journal:  Mol Divers       Date:  2016-08-01       Impact factor: 2.943

Review 3.  Therapeutic Opportunities in Eukaryotic Translation.

Authors:  Jennifer Chu; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 4.  Host-Directed Therapies for Tuberculosis.

Authors:  David M Tobin
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-18       Impact factor: 6.915

Review 5.  The eIF2-alpha kinase HRI: a potential target beyond the red blood cell.

Authors:  Nicholas Burwick; Bertal H Aktas
Journal:  Expert Opin Ther Targets       Date:  2017-10-30       Impact factor: 6.902

Review 6.  The integrated stress response: From mechanism to disease.

Authors:  Mauro Costa-Mattioli; Peter Walter
Journal:  Science       Date:  2020-04-24       Impact factor: 47.728

7.  Improved control of tuberculosis and activation of macrophages in mice lacking protein kinase R.

Authors:  Kangyun Wu; Jovanka Koo; Xiuju Jiang; Ran Chen; Stanley N Cohen; Carl Nathan
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

8.  High fructose and streptozotocin induced diabetic impairments are mitigated by Indirubin-3-hydrazone via downregulation of PKR pathway in Wistar rats.

Authors:  Mary Priyanka Udumula; Sureshbabu Mangali; Jaspreet Kalra; Deepika Dasari; Srashti Goyal; Vandana Krishna; Srivarsha Reddy Bollareddy; Dharamrajan Sriram; Arti Dhar; Audesh Bhat
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

9.  Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.

Authors:  Marzena Wojciechowska; Katarzyna Taylor; Krzysztof Sobczak; Marek Napierala; Wlodzimierz J Krzyzosiak
Journal:  RNA Biol       Date:  2014-04-24       Impact factor: 4.652

Review 10.  Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1.

Authors:  Marta López-Morató; John David Brook; Marzena Wojciechowska
Journal:  Front Neurol       Date:  2018-05-18       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.